logo-loader
viewKintara Therapeutics

Kintara Therapeutics and Kazia Therapeutics begin trial to treat deadly brain cancer, glioblastoma

Kintara Therapeutics Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive that its drug VAL-083 has been activated for an adaptive platform recurrent glioblastoma (GBM) trial.

Zarrabian says Kintara, along with Kazia Therapeutics Limited (ASX:KZA) (NASDAQ:KZIA) and its drug paxalisib, will collaborate with the Global Coalition for Adaptive Research and are entering the GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) trial that opened in July and has screened more than 370 patients to date.

Quick facts: Kintara Therapeutics

Price: 1.5 USD

NASDAQ:KTRA
Market: NASDAQ
Market Cap: $36.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kintara Therapeutics named herein, including the promotion by the Company of Kintara Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Alpha Growth's BlackOak Alpha Growth Fund generates positive returns despite...

Alpha Growth PLC (LON:ALGW) (OTCQB: ALPGF) CEO Gobind Sahney tells Proactive the financial services specialist's BlackOak Alpha Growth Fund produced a 2020 calendar year return of 10.63% and a 13.71% total return since inception in September 2019. Sahney says given the challenges of 2020, its...

8 hours, 36 minutes ago

2 min read